Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461584 | PMC |
| http://dx.doi.org/10.4103/jrms.JRMS_884_16 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prevalence and genomic insights of carbapenem resistant and ESBL producing Multidrug resistant Escherichia coli in urinary tract infections.
Sci Rep
January 2025
Department of Biotechnology, Faculty of Biomedical Sciences and Technology, Sri Ramachandra Institute of Higher Education and Research (SRIHER), Porur, Chennai, India.
Urinary tract infections are a common condition affecting people globally, with multidrug-resistant (MDR) Escherichia coli (E. coli) being a major causative agent. Antimicrobial susceptibility profiling was performed using the VITEK 2 automated system for 1254 E.
View Article and Find Full Text PDFEnhanced Killing of Methicillin-Resistant Staphylococcus aureus with Ceftaroline or Vancomycin in Combination with Carbapenems.
J Infect Dis
January 2025
Department of Pediatrics, University of California Irvine School of Medicine, Irvine, CA 92697, USA.
Background: Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia is associated with high rates of treatment failure, even when antibiotics showing in vitro susceptibility are used. Early optimization of therapy is crucial to reduce morbidity and mortality. Building on our previous research on carbapenem therapy for methicillin-susceptible S.
View Article and Find Full Text PDFDoripenem, Ertapenem, and Meropenem Sensitivity in Salmonella Typhi: A Cross-Sectional Study From Pakistan.
Cureus
November 2024
Department of Pharmacy, Hayatabad Medical Complex, Peshawar, PAK.
Background Typhi ( Typhi) is increasingly resistant to multiple antibiotics, posing a challenge in treatment, particularly in multidrug-resistant (MDR) cases. Carbapenems, including doripenem, ertapenem, and meropenem, have been considered last-resort options. This study evaluates the effectiveness of these carbapenems against Typhi isolates in a clinical setting in Peshawar, Pakistan.
View Article and Find Full Text PDFComprehensive Assessment of Initial Adaptation of ESBL Positive ST131 Escherichia coli to Carbapenem Exposure.
J Infect Dis
November 2024
Department of Infectious Diseases and Infection Control, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Background: It remains unclear how high-risk Escherichia coli lineages, like sequence type (ST) 131, initially adapt to carbapenem exposure in their progression to carbapenem resistance.
Methods: Carbapenem mutation frequency was measured in multiple subclades of extended-spectrum β-lactamase (ESBL) positive ST131 clinical isolates using a fluctuation assay followed by whole genome sequencing (WGS) characterization. Genomic, transcriptomic, and porin analyses of ST131 C2/H30Rx isolate, MB1860, under prolonged, increasing carbapenem exposure was performed using two experimental evolutionary platforms to measure fast vs.
[Prevalence and antimicrobial susceptibility of Klebsiella pneumoniae in a Cardiology Hospital].
Rev Med Inst Mex Seguro Soc
February 2024
Universidad Contemporánea de las Américas, Plantel Las Américas. Morelia, Michoacán, México.
Article Synopsis
- The study focuses on the increasing public health issue of multidrug-resistant Klebsiella pneumoniae (KP) strains in Mexico, highlighting the need for effective antibiotic policies due to rising resistance.
- It aims to assess the prevalence of ESBL (Extended Spectrum Beta-Lactamase) and non-ESBL KP strains, along with their susceptibility to various antimicrobials in patients with healthcare-associated infections at a cardiology hospital.
- Results from 2020 to 2023 showed that 9.5% of HAI cases were KP, with 49% being ESBL. The study found good sensitivity of both types to key antibiotics, emphasizing the importance of monitoring resistance to guide appropriate treatment decisions.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!